Particle-mediated (gene gun) in vivo delivery of the murine interleukin 12 (IL-12) gene in an expression plasmid was evaluated for antitumor activity. Transfer of IL-12 cDNA into epidermal cells overlying an implanted intradermal tumor resulted in detectable levels (266.0 ± 27.8 pg) of the transgenic protein at the skin tissue treatment site. Despite these low levels of transgenic IL-12, complete regression of established tumors (0.4-0.8 cm in diameter) was achieved in mice bearing Renca, MethA, SA-1, or L5178Y syngeneic tumors. Only one to four treatments with cDNA-coated particles, starting on day 7 after tumor cell implantation, were required to achieve complete tumor regression. This antitumor effect was CD8+ T cell-dependent and led to the generation of tumor-specific immunological memory. By using a metastatic P815 tumor model, we further showed that a delivery of IL-12 cDNA into the skin overlying an advanced intradermal tumor, followed by tumor excision and three additional (5, 6). However, systemic administration of rIL-12 caused dose-dependent toxicity in mice (7) and in human trials (8). Thus, a delivery mechanism that can provide relatively low levels of IL-12 at the target tissue might be advantageous in that it could generate an antitumor effect without causing systemic toxicity. Indeed, as cancer gene therapy has evolved, recent studies have produced encouraging results, showing that murine fibroblasts (9) or tumor cells (10) transduced in vitro with the IL-12 gene using a retroviral vector were able to induce antitumor immune responses. These data suggest that peritumoral IL-12 delivery may be as efficacious as systemic administration and avoid many undesirable side effects.
Interleukin 12 (IL-12), a bimolecular glycoprotein consisting of a 35-and a 40-kDa subunit, was originally identified as a factor that stimulates natural killer cells (1, 2) and promotes maturation of cytotoxic T lymphocytes (CTL) (3, 4) . It has recently been demonstrated that local or systemic treatment with recombinant (r) protein mediates profound antitumor effects in vivo, causing regression of established subcutaneous tumors and tumor metastases (5, 6) . However, systemic administration of rIL-12 caused dose-dependent toxicity in mice (7) and in human trials (8) . Thus, a delivery mechanism that can provide relatively low levels of IL-12 at the target tissue might be advantageous in that it could generate an antitumor effect without causing systemic toxicity. Indeed, as cancer gene therapy has evolved, recent studies have produced encouraging results, showing that murine fibroblasts (9) or tumor cells (10) transduced in vitro with the IL-12 gene using a retroviral vector were able to induce antitumor immune responses. These data suggest that peritumoral IL-12 delivery may be as efficacious as systemic administration and avoid many undesirable side effects.
The particle-mediated method for gene delivery by gene gun utilizes a shock wave to accelerate DNA-coated gold particles into target cells or tissues. At submicrogram quantities of DNA per dose for in vitro or in vivo gene transfer, the gene gun can deliver thousands of DNA copies intracellularly into test tissues, resulting in high level transgene expression (11) . As this method is cell surface receptor-independent, it can successfully deliver genes into a wide spectrum of mammalian cell types (12, 13) . We have recently demonstrated that a particlemediated, in vivo cytokine gene therapy reduces tumor growth in mice (14) . Treatments with interferon-y and tumor necrosis factor a shortly after the implantation of tumor cells inhibited tumor growth and prolonged the survival of tumor-bearing mice. To more closely approximate clinical situations, and to take advantage of the findings that IL-12 more effectively stimulates activated than naive T cells (15, 16) , we evaluated the effect of IL-12 gene therapy on the growth of established tumors. In this study, we utilized the gene gun technology for in vivo IL-12 cDNA delivery into the skin overlying the implanted, established tumor tissues.
MATERIALS AND METHODS
Mice. BALB/c, C57BL/6, DBA/2, and A/J female mice between 8 and 12 weeks of age were obtained from HarlanSparague-Dawley or Taconic Farms. All animal experiments were conducted in accordance with principles stated in ref. 17 .
Murine Tumor Models. Six established mouse tumor cell lines were employed in this study, namely Renca carcinoma, MethA sarcoma (both syngeneic in BALB/c mice), L5178Y lymphoma, P815 mastocytoma (both syngeneic in DBA/2 mice), SA-1 sarcoma, and B16 melanoma (syngeneic in A/J and C57BL/6 mice, respectively). Tumor cell cultures were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM L-glutamine, and gentamicin at 50 ,ug/ml. MethA sarcoma, SA-1 sarcoma, P815 mastocytoma, and L5178Y lymphoma were grown as ascites in syngeneic mice for 1 week before injecting intradermally (i.d.). Mice were shaved in the abdominal area and injected i.d. with 1 x 106 (or 1 x 105, in the case of B16-tumor) tumor cells in 50 ,ul phosphate-buffered saline (PBS). Tumor growth was monitored two to three times a week by measuring two perpendicular tumor diameters using calipers. Gene Expression Vector. We constructed a plasmid (pWRG3169) containing coding sequences for the p35 and p40 subunits of murine (m) IL-12, linked tandomly in the same direction and each driven by its own cytomegalovirus (CMV) i/e promoter/enhancer, a simian virus 40 (SV40) sd/sa intron sequence, and a bovine growth hormone polyadenylylation sequence. The murine 35-and 40-kDa IL-12 subunit cDNA clones were isolated from mouse lymphocyte cDNA libraries by PCR cloning. The PUC19 plasmid backbone was derived from a bluescript SK(+) vector with an ampicillin-resistance gene (see Fig. 1A ). A control vector containing a luciferase Abbreviations: IL-12, interleukin 12; CTL, cytotoxic T lymphocyte; mAb, monoclonal antibody; r, recombinant; m, murine; CMV, cytomegalovirus; SV40, simian virus 40; Luc, luciferase. §To whom reprint requests should be addressed.
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(Luc) cDNA expression plasmid containing the CMV promoter was constructed as described by Cheng et al. (12) .
In Vivo and in Vitro Gene Transfer. The experiments utilized a helium-pulse Accell (gene gun) device that was designed by D. McCabe (Agracetus, Inc). Plasmid DNA was precipitated onto 2 ,um gold particles. Particles were suspended in a solution of 0.1 mg of polyvinyl pyrrolidone per ml in absolute ethanol. This DNA/gold/particle preparation was coated onto the inner surface of a Tefzel tubing by using a tube loader (Agracetus), and the tubing was cut into 0.5-inch segments to result in delivery of 0.5 mg gold and 1.25 ,ug plasmid DNA per transfection. For tumor therapy, mouse skin overlying and surrounding the target tumor was transfected in vivo with IL-12 or Luc cDNA expression vectors starting from day 7 after i.d. implantation of 1 x 106 of five different types of tumor cells, except for B16 tumor, which was implanted at 105 cells. Each treatment consisted of four transfections (5 ,ug plasmid DNA/ treatment) with a 300 psi helium gas pulse. One transfection was directly over the tumor site, and three additional treatments were evenly spaced around the circumference of the tumor in a triangle pattern. The in vitro particle bombardment gene transfer was performed as described (18) . Bioassay. For determining transgenic IL-12 expression following in vivo gene transfer, blood was obtained by cardiac puncture, and skin tissue samples containing four transfection sites were collected in 0.5 ml of general extraction buffer, thoroughly minced with scissors, and sonicated before collecting the supernatant. The level of transgenic IL-12 protein was determined by a cell proliferation bioassay by using murine Con A-activated splenocytes as described (19 LJL~s was used as a standard. Anti-mIL-12 monoclonal antibody (mAb) (kindly provided by M. Gately, Hoffman-La Roche) was used to ensure that the bioactivity of the samples was due to IL-12. The sensitivity of this assay was about 10 pg/ml for rIL-12 standard protein and cell culture samples, and about 100 pg/ml for serum and skin tissue extracts.
Immunohistochemistry. The in vivo transfected skin tissues were sectioned in a cryostat (8 mm), placed on silanated slides and allowed to air dry. Test tissues were then fixed with acetone at 4°C for 10 min, air dried, washed in PBS for 10 min, and incubated with the anti-IL12 mAb (10 mg/ml) for 60 min at room temperature. Reacted tissues were rinsed two times in PBS and incubated with a biotinylated secondary antibody (rabbit anti-rat IgG; Vector Laboratories) for 60 min at room temperature. After rinsing with PBS, localization of the antibody binding was visualized with peroxidase staining and developed with metal enhanced 3,3-diaminobenzidine-H202.
Sections were rinsed in PBS and counterstained with hematoxylin, dehydrated in ethanol, treated with xylene, and mounted with permount.
IL-12 Gene Therapy of Spontaneous Metastasis. A spontaneous metastasis model using weakly immunogenic P815 tumor has been described (20) . DBA/2 mice were injected i.d. with 1 x 106 P815 cells. The skin overlying and surrounding the tumor was transfected with IL-12 cDNA or Luc cDNA on days 12 and 14 of tumor growth. Surgical excision of the tumor was performed on day 15 of tumor growth, and additional transfections of the skin on both sides of abdomen were performed on days 16, 18, and 20. Survival of the mice was followed.
Generation of Cytotoxic T Lymphocytes and Cytotoxic Assay. Tumor-specific CTL were generated in vitro as described (21 (Fig. 1B) .
Tumor Regression and Suppression of Tumor Growth Following IL-12 Gene Therapy. It is known that certain murine immunogenic tumors can induce a T cell-mediated immune response that is best detected on days 7-9 of tumor growth in defined tumor models (22) (23) (24) . Therefore we started the IL-12 cDNA treatments at 7 days postimplantation of tumor cells with the hope of enhancing the already activated endogenous antitumor immune response. Using this experimental strategy, the in vivo delivery of the chimeric IL-12 genes into skin tissues overlying established 7-day tumors resulted in complete tumor regression or suppression of tumor growth in four tumor models (Figs. 1C and 2) . In mice bearing Renca, L5178Y, MethA, or SA-1 tumors, complete tumor regression was achieved in 87.5% (7/8), 87.5% (7/8), 57% (4/7), and 37.5% (3/8) of the tested mice, respectively (Fig. 2) (Fig. 2) . Furthermore, in mice bearing P815 mastocytoma or B16 melanoma, a significant suppression of tumor growth was achieved (Fig. 2) (14) , indicate that transgenic IL-12 production by normal epidermal cells in the vicinity of the tumor is responsible for the antitumor effect of IL-12 gene therapy. Therefore, the in vivo, particle-mediated IL-12 gene transfer protocol is drastically different from other currently employed procedures of cancer gene therapy, where a therapeutic vector is either introduced into the tumor or other cells in vitro, or injected directly into the tumor mass in vivo.
Involvement of CD8+ T Cells in Tumor Regression. To determine the role of CD4+ and CD8+ T cells in the observed tumor regression, we injected Renca tumor-bearing mice with anti-CD4 or anti-CD8 mAb on the next day after the beginning of IL-12 gene therapy and then 4 days later. This protocol was based on our previous findings showing that the same mAbs caused depletion of more than 90% of relevant T cell subsets in mice for 4-5 days following a single injection (25, 26) . (20) . In this system, an excision of the primary P815 tumor on day 12 (data not shown) or day 15 (Fig. 4) posttumor implantation was followed by death of all treated mice by day 37 or 29, respectively. However, when the skin overlying the i.d. P815 tumors were transfected with IL-12 cDNA on days 12 and 14 posttumor cell implantation, followed by tumor excision on day 15, and three additional IL-12 cDNA skin transfections at the abdominal sites adjacent to the excised primary tumor, a significant prolongation of the survival was observed (Fig. 4) 28 .0 ± 0.6 days after tumor cell implantation. Death was caused by spontaneous metastases of tumor cells into the internal organs, primarily the liver, as was evidenced by macroscopic examination (data not shown). IL-12 gene therapy effectively prolonged the survival of mice (survival time 41.4 ± 4.9 days, P < 0.05), and one of eight mice was "cured." This experiment was repeated without additional transfections posttumor excision, and we observed that all of the Luc cDNA treated mice (n = 11) died in 43.9 ± 7.1 days, whereas 5 of 12 (41.6%) IL-12 gene therapy-treated mice survived for at least 180 days and thus were considered cured. The experiment was repeated using mice that rejected L5178Y tumors and were secondarily challenged with L5178Y or P815 tumor cells, and similar results were obtained. (B) Induction of CTL activity in mice that rejected tumors following IL-12 gene therapy. Tumor-specific CTL were generated in vitro as described. Mean ± SEM of four mice per group. Spleen cells from IL-12 gene-treated mice generated 3-to 4-fold higher levels of CTL activity than spleen cells from naive mice (P < 0.005). augment systemic antitumor immune response even against a weakly immunogenic tumor, and this can lead to eradication of established spontaneous metastases in mice. Therefore, such human metastatic cancers as subcutaneous T-cell lymphoma or melanoma may provide excellent models for future clinical application of the current IL-12 gene therapy approach.
Immunological (Fig. SB) . In a similar study, using mice that rejected L5178Y tumors, we found that the generated CTL were tumor-specific, in that they lysed the L5178Y target tumor cells but not the syngeneic P815 target cells (data not shown).
Our study shows that gene gun-mediated in vivo delivery of an IL-12 expression plasmid into skin tissue overlying tumor sites is an effective approach for tumor immunotherapy in various murine tumor models, leading to eradication or suppression of established intradermal tumors and their spontaneous metastases. Remarkably, the local amount of detectable IL-12 at the treatment tissue site is 1/400 to 1/40,000 of the dosage of rIL-12 protein employed for efficacy studies in the same or similar mouse tumor models (5, 6, 33) . In view of the apparent dose dependent toxicity of human rIL-12 protein in clinical trials (8) 
